Table 1.

Characteristics of patients treated with ibrutinib according to subtype

CharacteristicAll patients (n = 54)Non-GCB (n = 24)GCB (n = 11)RT (n = 13)Unknown (n = 6)P
Age at diagnosis, y, median (range)62 (38-88)61 (38-88)61 (47-79)61 (47-80)68 (40-71).97
Sex, no. (%)
 Men33 (61)15 (63)4 (36)9 (69)5 (83).27
 Women21 (39)9 (37)7 (64)4 (31)1 (17)
IPI at diagnosis, no. (%)
 Low14 (26)5 (21)4 (36)4 (31)1 (17).78
 Low intermediate11 (20)7 (29)1 (9)2 (15)1 (17)
 High intermediate13 (24)7 (29)1 (9)3 (23)2 (33)
 High16 (30)5 (21)5 (46)4 (31)2 (33)
Number of prior treatments
 Median3333.04.61
 Range1-111-82-81-112-5
Prior transplant,* no. (%)17 (31)6 (25)5 (46)3 (23)3 (50).42
CNS disease at diagnosis, no. (%)6 (11)4 (17)0 (0)1 (8)1 (17).53
  • CNS, central nervous system; IPI, International Prognostic Index.

  • * All transplants were autologous except 2, who received allogeneic transplants (1 with GCB subtype and 1 with non-GCB subtype).